Literature DB >> 27045333

Comorbidity in rheumatoid arthritis.

Carl Turesson1.   

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory condition, which is associated with an increased risk of comorbidity from other diseases. RA disease severity is a major predictor of development of cardiovascular disease, serious infections and malignant lymphoma. This reflects the role of chronic inflammation in the underlying pathology. Recent surveys indicate that although clinical outcomes have improved in patients with RA, mainly owing to access to more efficient pharmacotherapy, comorbidity remains a major issue in many patients. Register-based observational studies are useful sources of information on the impact of comorbidity and the efficacy and safety of antirheumatic treatment in patients with coexisting diseases. As a part of strategies to improve further the management of patients with RA, multidisciplinary collaboration for prevention and early detection of comorbidities is of major importance.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27045333     DOI: 10.4414/smw.2016.14290

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  16 in total

1.  Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty.

Authors:  Julio J Jauregui; J Paul Hovis; S Ashfaq Hasan
Journal:  Clin Rheumatol       Date:  2017-05-24       Impact factor: 2.980

2.  Fluorine-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin/inflammatory of unknown origin patients.

Authors:  Ziwei Chen; Yuan Li; Qian Wang; Shijia Weng; Yunshan Zhou; Jihong Zhu
Journal:  Clin Rheumatol       Date:  2021-10-21       Impact factor: 2.980

3.  One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Authors:  Leslie R Harrold; Heather J Litman; Katherine C Saunders; Kimberly J Dandreo; Bernice Gershenson; Jeffrey D Greenberg; Robert Low; Jeffrey Stark; Robert Suruki; Srihari Jaganathan; Joel M Kremer; Mohamed Yassine
Journal:  Arthritis Res Ther       Date:  2018-01-02       Impact factor: 5.156

4.  Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis.

Authors:  Bei Xu; Jin Lin
Journal:  PeerJ       Date:  2017-11-24       Impact factor: 2.984

Review 5.  The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.

Authors:  Federico Biscetti; Andrea Flex; Stefano Alivernini; Barbara Tolusso; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Mediators Inflamm       Date:  2017-10-23       Impact factor: 4.711

Review 6.  COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.

Authors:  Dieu-Donné Ouédraogo; Wendlassida Joelle Stéphanie Tiendrébéogo; Fulgence Kaboré; Honoré Ntsiba
Journal:  Clin Rheumatol       Date:  2020-05-29       Impact factor: 2.980

7.  Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.

Authors:  Michalis P Migkos; Evripidis Kaltsonoudis; Eleftherios Pelechas; Vassiliki Drossou; Panagiota G Karagianni; Athanasios Kavvadias; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2021-03-03       Impact factor: 2.631

8.  Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.

Authors:  Jeffrey R Curtis; Kevin Winthrop; Cathy O'Brien; Matladi N Ndlovu; Marc de Longueville; Boulos Haraoui
Journal:  Arthritis Res Ther       Date:  2017-12-15       Impact factor: 5.156

9.  Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink.

Authors:  Rebecca M Joseph; Mohammad Movahedi; William G Dixon; Deborah Pm Symmons
Journal:  RMD Open       Date:  2017-09-26

10.  IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors.

Authors:  James W Swann; Lada A Koneva; Daniel Regan-Komito; Stephen N Sansom; Fiona Powrie; Thibault Griseri
Journal:  J Exp Med       Date:  2020-09-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.